Open Issues in the Choice and Management of Direct Oral Anticoagulants in Patients with Cancer-Related Venous Thromboembolism

Daniele Pastori; Gualtiero Palareti

doi:10.1055/s-0044-1788997

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2024; 124(11): 1024-1026
DOI: 10.1055/s-0044-1788997

Invited Editorial Focus

Open Issues in the Choice and Management of Direct Oral Anticoagulants in Patients with Cancer-Related Venous Thromboembolism

Authors

Daniele Pastori

¹Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
Gualtiero Palareti

²Fondazione Arianna Anticoagulazione, Bologna, Italy

Abstract

Volltext

Referenzen

References
1 Sueta D, Yamashita Y, Morimoto T. et al; COMMAND VTE Registry-2 Investigators. Edoxaban, rivaroxaban, or apixaban for cancer-associated venous thromboembolism in the real world: insights from the COMMAND VTE Registry-2. Thromb Haemost 2024; 124 (11) 1013-1023
2 Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020; 120 (04) 702-713
3 Danilatou V, Dimopoulos D, Kostoulas T, Douketis J. Machine learning-based predictive models for patients with venous thromboembolism: a systematic review. Thromb Haemost 2024; 124 (11) 1040-1052
4 Tian L, Li W, Su Y. et al. Risk factors for central venous access device-related thrombosis in hospitalized children: a systematic review and meta-analysis. Thromb Haemost 2021; 121 (05) 625-640
5 Ma Z, Sun X, Zhang Y. et al. Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials. Thromb Haemost 2022; 122 (10) 1757-1766
6 Mahé I, Agnelli G, Ay C. et al. Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study. Thromb Haemost 2022; 122 (04) 646-656
7 Kim SA, Lee JH, Lee JY. et al. Treatment and bleeding complications of cancer-associated venous thromboembolism: a Korean population-based study. Thromb Haemost 2022; 122 (12) 2011-2018
8 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
9 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
10 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects. Thromb Haemost 2024; 124 (09) 842-851
11 Roy DC, Wang TF, Mallick R. et al. Growth differentiation factor-15, high-sensitivity cardiac troponin T, and N-terminal pro-B-type natriuretic peptide for predicting risk of venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2022; 122 (07) 1169-1176
12 Rønnow Sand J, Troelsen FS, Nagy D. et al. Increased cancer risk in patients with kidney disease and venous thromboembolism: a population-based cohort study. Thromb Haemost 2023; 123 (12) 1165-1176
13 le Sève JD, Guédon AF, Bordenave S. et al. Risk factors of venous thromboembolic disease in cancer patients treated with immune checkpoint inhibitor. Thromb Haemost 2023; 123 (11) 1049-1056
14 Konstantinides SV, Meyer G, Becattini C. et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
15 Stevens SM, Woller SC, Kreuziger LB. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160 (06) e545-e608
16 Cohen AT, Creeper KJ, Alikhan R. et al. Early time courses of recurrent venous thromboembolism and bleeding during apixaban or dalteparin therapy for patients with cancer. Thromb Haemost 2024; 124 (07) 676-683
17 Cohen AT, Wallenhorst C, Rivera M. et al. Comparison of clinical outcomes in patients with active cancer receiving rivaroxaban or low-molecular-weight heparin: the OSCAR-UK study. Thromb Haemost 2024; (e-pub ahead of print).
18 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
19 Pastori D, Cormaci VM, Marucci S. et al. A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int J Mol Sci 2023; 24 (04) 3169